Cargando…
Cost Utility of Omalizumab Compared with Standard of Care for the Treatment of Chronic Spontaneous Urticaria
BACKGROUND: Chronic spontaneous urticaria (CSU) negatively impacts patient quality of life and productivity and is associated with considerable indirect costs to society. OBJECTIVE: The aim of this study was to assess the cost utility of add-on omalizumab treatment compared with standard of care (SO...
Autores principales: | Graham, Jonathan, McBride, Doreen, Stull, Donald, Halliday, Anna, Alexopoulos, Stamatia Theodora, Balp, Maria-Magdalena, Griffiths, Matthew, Agirrezabal, Ion, Zuberbier, Torsten, Brennan, Alan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4929169/ https://www.ncbi.nlm.nih.gov/pubmed/27209583 http://dx.doi.org/10.1007/s40273-016-0412-1 |
Ejemplares similares
-
EQ-5D Utilities in Chronic Spontaneous/Idiopathic Urticaria
por: Hawe, Emma, et al.
Publicado: (2016) -
Assessing Changes in Chronic Spontaneous/Idiopathic Urticaria: Comparisons of Patient-Reported Outcomes Using Latent Growth Modeling
por: Stull, Donald E., et al.
Publicado: (2016) -
Omalizumab for Patients with Chronic Spontaneous Urticaria: A Narrative Review of Current Status
por: Casale, Thomas B., et al.
Publicado: (2023) -
Improvement of sleep in patients with chronic idiopathic/spontaneous urticaria treated with omalizumab: results of three randomized, double-blind, placebo-controlled studies
por: Gimenéz-Arnau, Ana M., et al.
Publicado: (2016) -
Omalizumab substantially improves dermatology‐related quality of life in patients with chronic spontaneous urticaria
por: Finlay, A.Y., et al.
Publicado: (2017)